NR3C1 and breast carcinoma: Inspired by these findings, we used various epigenetic inhibitors (that block action of either HDACs or BRDs) to position these as promising therapeutic strategies for cancers that do not have an active GR‐signaling axis, such as luminal B breast cancers.